UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients

Annals of oncology, 2008-02, Vol.19 (2), p.332-339

2008

Volltextzugriff (PDF)

Pharmacokinetics of Tilidine in Terminal Renal Failure

Journal of clinical pharmacology, 2001-01, Vol.41 (1), p.79-84

2001

Volltextzugriff (PDF)

Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients

Clinical microbiology and infection, 2002-01, Vol.8 (1), p.14-25

2002

Volltextzugriff (PDF)

Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2

European journal of cancer (1990), 1997-06, Vol.33 (7), p.1050-1054

1997

Volltextzugriff (PDF)

Cytokines in clinical cancer treatment trials: Methodological aspects

European journal of cancer (1990), 1994, Vol.30 (3), p.412-414

1994

Volltextzugriff (PDF)

Tilidine does not affect human sphincter of Oddi motility—a randomized, controlled study

Alimentary pharmacology & therapeutics, 1997-10, Vol.11 (5), p.987-992

1997

Volltextzugriff (PDF)

Molecular organization of the human Raf-1 promoter region

Molecular and Cellular Biology, 1990-07, Vol.10 (7), p.3325-3333

1990

Volltextzugriff (PDF)

Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine

Molecular pharmacology, 1991-02, Vol.39 (2), p.171-176

1991

Volltextzugriff (PDF)

The Complete Sequence and Promoter Activity of the Human A- raf-1 Gene (ARAF1)

Genomics (San Diego, Calif.), 1994-03, Vol.20 (1), p.43-55

1994

Volltextzugriff (PDF)

Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: FISH results

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.7160-7160

2006

Volltextzugriff (PDF)

Dacarbazine and interferon alpha for stage IV malignant melanoma

Oncology, 1997-07, Vol.54 (4), p.270-274

1997

Volltextzugriff (PDF)

Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene

Journal of molecular medicine (Berlin, Germany), 1997-04, Vol.75 (4), p.297-299

1997

Volltextzugriff (PDF)

Pilot study for the evaluation of T-cell-mediated tumor immunotherapy by cytokine gene transfer in patients with malignant tumors

Journal of molecular medicine (Berlin, Germany), 1995-04, Vol.73 (4), p.205-206

1995

Volltextzugriff (PDF)

Loss of heterozygosity at the c-raf locus in small cell lung carcinoma

Oncogene, 1989-04, Vol.4 (4), p.451-456

1989

Volltextzugriff (PDF)

Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +/- erlotinib (TALENT)

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.7028-7028

2005

Volltextzugriff (PDF)

Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: preliminary results

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.7100-7100

2005

Volltextzugriff (PDF)

raf oncogenes in carcinogenesis

Critical reviews in oncogenesis, 1990, Vol.2 (1), p.1

1990

Volltextzugriff (PDF)

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.7010-7010

2004

Volltextzugriff (PDF)

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.7010-7010

2004

Volltextzugriff (PDF)

PD-155 Molecular markers such as EGFR and kRAS mutations aspredictors of sensitivity to erlotinib in patients (pts) with NSCLC: Exploratory subanalyses of TALENT, a phase III trial

Lung cancer (Amsterdam, Netherlands), 2005-07, Vol.49, p.S112-S112

2005

Volltextzugriff (PDF)

P-949 Phase II pharmacodynamic trial of erlotinib in advancednon-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy

Lung cancer (Amsterdam, Netherlands), 2005-07, Vol.49, p.S369-S369

2005

Volltextzugriff (PDF)

Processing of tumor tissues for vaccination with autologous tumor cells

European surgical research, 1997, Vol.29 (4), p.292-302

1997

Volltextzugriff (PDF)

A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3585-3585

2004

Volltextzugriff (PDF)

A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3585-3585

2004

Volltextzugriff (PDF)

Pharmacokinetics of nortilidine and naloxone after administration of tilidine/naloxone solution or tilidine/naloxone sustained release tablets

Arzneimittel-Forschung, 2000-11, Vol.50 (11), p.1015-1022

2000

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients

Pharmacokinetics of Tilidine in Terminal Renal Failure

Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients

Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2

Cytokines in clinical cancer treatment trials: Methodological aspects

Tilidine does not affect human sphincter of Oddi motility—a randomized, controlled study

Molecular organization of the human Raf-1 promoter region

Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine

The Complete Sequence and Promoter Activity of the Human A- raf-1 Gene (ARAF1)

Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: FISH results

Dacarbazine and interferon alpha for stage IV malignant melanoma

Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene

Pilot study for the evaluation of T-cell-mediated tumor immunotherapy by cytokine gene transfer in patients with malignant tumors

Loss of heterozygosity at the c-raf locus in small cell lung carcinoma

Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +/- erlotinib (TALENT)

Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: preliminary results

raf oncogenes in carcinogenesis

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

PD-155 Molecular markers such as EGFR and kRAS mutations aspredictors of sensitivity to erlotinib in patients (pts) with NSCLC: Exploratory subanalyses of TALENT, a phase III trial

P-949 Phase II pharmacodynamic trial of erlotinib in advancednon-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy

Processing of tumor tissues for vaccination with autologous tumor cells

A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients

A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients

Pharmacokinetics of nortilidine and naloxone after administration of tilidine/naloxone solution or tilidine/naloxone sustained release tablets

Suchergebnisse filtern